29 C
Vientiane
Tuesday, August 5, 2025
spot_img
Home Blog Page 22

Thailand, Cambodia Trade Accusations Ahead of Key Border Talks

Following the border dispute between Thailand and Cambodia on 28 May 2025, Thai Government Spokesperson Jirayu Huangsap reaffirmed Thailand’s commitment to peacefully resolve the issue through dialogue and legal agreements. (Photo: Royal Thai Government)

Tensions are rising along the Thailand-Cambodia border as both sides trade accusations of military provocations ahead of the General Border Committee (GBC) meeting from 4 to 7 in Kuala Lumpur. Although the border remains calm, troops are on high alert amid warnings of ceasefire violations and misinformation.

Advancing Global Tourism Industry Trade: Tourism Plus Shanghai 2026 Calls for Worldwide Exhibitors

SHANGHAI, Aug. 4, 2025 /PRNewswire/ — From March 29th to April 3rd, 2026, Tourism Plus Shanghai (TPS 2026) will convene over 6,000 global exhibitors in Shanghai, China, showcasing comprehensive solutions across the tourism and lifestyle sectors — spanning catering, accommodation, transportation, sightseeing, shopping, and entertainment. Visitor attendance is projected to exceed the 2025 record of 445,737 participants from 148 countries and regions. 

Tourism Plus Shanghai (TPS 2026) is guided by Shanghai Municipal Administration of Culture and Tourism, co-sponsored by China Tourism Association, and hosted by Shanghai Sinoexpo Informa Markets International Exhibition Co., Ltd. and Shanghai International Convention & Exhibition Co., Ltd. The expo accelerates the deep integration of “tourism + industries” and “industries + tourism”, catalyzing innovation in hospitality, retail, sports, and related sectors. It fosters emerging business models and establishes a new framework for global tourism industry development. Suppliers of tourism services, catering supply chain, hotel supplies, retail technology and equipment, boat and outdoor products, and entertainment projects will present their latest products and services to international buyers. 

Concurrently, TPS 2026 provides a strategic platform for overseas destinations to access the Chinese market and facilitates partnerships with Chinese investors and trade entities. Through targeted matchmaking conferences and digital tools, the event bridges global supply chains with demand-driven opportunities. 

Three Major Venues in Shanghai Host 42 Exhibition Categories

March 29th-31st, 2026

Shanghai World Expo Exhibition & Convention CenterTourist Destinations & Road trip route | Tourism & Cultural Technology | Tourism Operation & Facilities | Tourism & Cultural Consumption | Outdoor Sports | Health Plus | Boat | Boat Equipment and Accessories | Boat Service | Water sports | BBDS | Lure Fishing l Design company | Manufacturing factory | Internet-famous Prop | Light-based Art Display

March 30thApril 2nd, 2026

National Exhibition and Convention Center (Shanghai)Catering Equipment & Supplies | Central Kitchen Equipment & Food Machinery and Equipment | Refrigeration Equipment | Tableware | Finefood | Beverage | Coffee &Tea | Ice Cream & Dairy | Baking Equipment & Raw Materials | Food & Catering Packaging | The Bar & Drinks | Brand Franchising & Chain Store Resources

March 31stApril 3rd, 2026

Shanghai New International Expo Center:Hotel Supplies | Smart Hotel | Hotel Franchise | Building & Decoration | Engineering Design | Lighting | Commercial Retail | Smart Office | Landscape Gardens | Hotel Furniture | Sunshading Material | Cleaning Operation & Maintenance | Property Management | Urban Appearance & Environmental Sanitation

From March 29th-April 3rd, 2026, we hope to see you in Shanghai, China.

Website: www.lbhgle.com/en-tps 

Contact: Betty Hu
Mail: Betty.Hu@informa.com  

RHB, TOKIO MARINE LIFE AND TAKAFUL MALAYSIA FORGE LONG TERM EXCLUSIVE BANCA PARTNERSHIPS

KUALA LUMPUR, Malaysia, Aug. 4, 2025 /PRNewswire/ — RHB Banking Group (“RHB” or the “Group”) entered into bancassurance and bancatakaful partnerships with Tokio Marine Life Insurance Malaysia Bhd. (“Tokio Marine Life”) and its takaful partners – Syarikat Takaful Malaysia Keluarga Berhad (“STMKB”), and its wholly owned subsidiary, Syarikat Takaful Malaysia Am Berhad (“STMAB”) (collectively referred to as “Takaful Malaysia”). These partnerships are formalised through separate Distribution Agreements – between RHB Bank and Tokio Marine Life, and between RHB Islamic and Takaful Malaysia, as well as the Framework Agreement entered into by all parties.

Under the Distribution Agreements, RHB will exclusively sell, distribute, market and promote the conventional life insurance products, the family takaful products and the general takaful products developed by Tokio Marine Life and Takaful Malaysia, in Malaysia. The Framework Agreement is entered into as part of the overall joint operating and governance framework for the banca partnerships.

The exclusive Distribution Agreements will be for a period of 20 years commencing 1 August 2025, at a Total Access Fee payable to RHB of up to RM1.6 billion. The Total Access Fee reflects the projected insurance and takaful business volume that RHB is expected to generate over the tenure of the Distribution Agreements, including anticipated sales of products through RHB’s network of branches and digital channels. These will contribute positively to the Group’s profit before tax.

Dato’ Mohd Rashid Mohamad, Group Managing Director/Group Chief Executive Officer of RHB Banking Group said, “This long term and exclusive banca partnerships reinforces our commitment to staying relevant to our customers, diversifying our income streams and driving sustainable long-term growth. By deepening our collaboration, we are able to deliver tailored financial solutions, enhance customer experience and unlock meaningful value for RHB as well as our banca partners. This aligns with our PROGRESS27 strategic priorities, which is already in motion, enabling us to deliver broader value to our stakeholders while driving our non-interest income streams.”

“This reflects the strength, resilience and maturity of our partnership. One that we have built over the years of collaboration and shared ambition. We are confident that this next chapter will see us deliver even greater value to the community, combining Tokio Marine’s global insurance expertise with RHB’s local reach and customer trust,” said Toi See Jong, Chief Executive Officer of Tokio Marine Life Insurance Malaysia Bhd.

Additionally, Nor Azman Zainal, Group Chief Executive Officer of Takaful Malaysia said, “This collaboration positions us to scale our takaful offerings and broaden our footprint within the Islamic financial ecosystem. It reflects our ongoing commitment to making ethical, Shariah-compliant protection more accessible to a wider base of consumers across our key markets.”

The product portfolio will continue to evolve in response to customer needs and emerging market trends.

Issued on behalf of RHB Bank Berhad by the Corporate Communications & Media Relations division.

For media enquiries, please contact Nishanthi Palani at nishanthi.palani@rhbgroup.com / 012-420 0812 or Joanne Lim at joanne.lim@rhbgroup.com / 012-304 7604

Customers may call our Customer Contact Centre at 03–9206 8118 for enquiries on RHB’s products and services.

About RHB Banking Group

RHB Banking Group is one of Malaysia’s longest-standing and leading financial institutions, with a proud heritage spanning over a century. Headquartered in Kuala Lumpur, Malaysia, the Group has a strong presence across seven ASEAN markets and is powered by a workforce of over 13,000 employees. United by a common purpose – Together We Progress – RHB is committed to empowering individuals, businesses and communities to grow and progress together.

As a fully integrated financial group, our core businesses are structured into six key pillars: Group Community Banking, Group Corporate & Business Banking, Group Wholesale Banking, Group Shariah Business, Group International Business and Group Insurance. We offer comprehensive and innovative financial solutions through RHB Bank Berhad and our key subsidiaries: RHB Investment Bank Berhad, RHB Islamic Bank Berhad, and RHB Insurance Berhad. Our asset management and unit trust businesses are undertaken by RHB Asset Management Sdn. Bhd. and RHB Islamic International Asset Management Berhad.

RHB Bank Berhad is listed on Bursa Malaysia with a market capitalisation of RM27 billion (as at 30 July 2025).

Guided by our purpose, RHB is focused on delivering meaningful and sustainable value by driving innovation, fostering inclusive growth, and strengthening long-term resilience to meet the evolving needs of our customers, communities, and the broader financial ecosystem.

For more information, please visit www.rhbgroup.com.

Malaysia | Singapore | Indonesia | Thailand | Brunei | Cambodia | Lao PDR

About Tokio Marine Life Insurance Malaysia Bhd.

Tokio Marine Life Insurance Malaysia Bhd. (“TMLM”) has over 75 years of presence in Malaysia and is financially strong with total assets of over RM12 billion**. Today, Tokio Marine Life is a member of Tokio Marine Group in Japan with more than 43,000 employees worldwide and operates in 45 countries and regions. The core company of Tokio Marine Group, Tokio Marine Nichido Fire is financially strong with net asset worth JPY 3,208,837 million+ and Tokio Marine Holdings with net asset worth JPY 5,103,545 million+ (consolidated) has a credit rating of A+ by Standard and Poor’s, Aa3 by Moody’s and A++ (Stable) by A.M. Best.

**As of 31 December 2024

As of March 2025

 

For more information, please visit www.tokiomarine.com

For media inquiries, please contact our Corporate Communications & Advertising department at: communications@tokiomarinelife.com.my

About Takaful Malaysia

Syarikat Takaful Malaysia Berhad (“STMB”) was incorporated on 29 November 1984. In accordance with the Islamic Financial Services Act 2013 (“IFSA”), STMB separated its composite license into two (2) licensed entities on 1 June 2018. STMB, now known as Syarikat Takaful Malaysia Keluarga Berhad (“Takaful Malaysia” or “Takaful Malaysia Keluarga”) manages the Family Takaful business whilst Syarikat Takaful Malaysia Am Berhad (“Takaful Malaysia Am”) manages the General Takaful business. Takaful Malaysia Keluarga is the holding company and owns 100% of Takaful Malaysia Am, and the Company has a share capital of RM357.87 million with total assets of RM17.2 billion at the Group level as at 31 March 2025. Both companies operate through the Takaful Malaysia brand with a combined network of branches in 23 locations nationwide. 

For media enquiries, please contact Firdaus Nasir at firdaus.nasir@takaful-malaysia.com.my / 012-295 1081.

Government-Private Sector-Civil Society Unite with Global Experts to Accelerate Green Transition Propelling Thailand Toward Low-Carbon Society

Driving Two Key Agendas to Strengthen Global Competitiveness


BANGKOK, THAILAND – Media OutReach Newswire – 4 August 2025 SCG organized the ESG Symposium 2025 under the concept “GREEN BREAKTHROUGH AMID THE PERFECT STORM” at SCG Headquarters, Bangkok. The event drew over 300 participants comprising key stakeholders driving Green Transition from government, private sector, civil society, and world-class experts who gathered to brainstorm and advance crucial collaboration for transitioning Thailand and the ASEAN region toward a fair and sustainable low-carbon society.

Leading international speakers sharing perspectives and approaches for transitioning to sustainability at the ESG Symposium 2025 at SCG Headquarters, Bangkok, Thailand
Leading international speakers sharing perspectives and approaches for transitioning to sustainability at the ESG Symposium 2025 at SCG Headquarters, Bangkok, Thailand

The symposium facilitated policy and practical exchanges on two fundamental agendas that serve as critical keys to the transition, working together to reach conclusions for driving the low-carbon society forward: 1) Energy Transition aimed at elevating energy systems to align with Net Zero targets, and 2) Just Transition for SMEs creating opportunities for small and medium enterprises to genuinely access ESG mechanisms.

The forum was honored by global leaders including Mr. Koji Sato – President and CEO, Toyota Motor Corporation, Mr. David McLachlan-Karr – Regional Director, UN Development Coordination Office (DCO), Asia-Pacific, and researchers from MIT including Dr. Sai Ravela – Principal Research Scientist, Earth, Atmospheric and Planetary Sciences (EAPS), MIT and Prof. Miho Mazereeuw – Director of MIT Climate Mission and Director of Urban Risk Lab, MIT, alongside Dr. ​Sethaput Suthiwartnarueput, Governor of the Bank of Thailand, who presented approaches for adaptation, building resilience, and enhancing Thailand’s long-term competitiveness.

ESG Symposium 2025 represents a collaborative platform where all sectors join forces to accelerate the creation of a sustainable regional future, connecting environmental objectives with economic opportunities and preparing ASEAN to address a rapidly changing world.

Hashtag: #esgsymposium2025 #GreenBreakthroughAmidThePerfectStorm

The issuer is solely responsible for the content of this announcement.

Elegoo Launches Nexprint, an Open-Source 3D Model Platform for Global Creators

SHENZHEN, China, Aug. 4, 2025 /PRNewswire/ — Elegoo, a rapidly developing brand in global smart manufacturing, today unveils Nexprint, an open-source platform designed to connect creators worldwide by enabling seamless sharing and downloading of 3D models. The platform aims to foster a global creative hub that streamlines printing workflow for all-level 3D printer users, connects global creators and rewards their original designs. 

Nexprint——Turn Your Ideas into Prints
Nexprint——Turn Your Ideas into Prints

We believe everyone can enjoy the fun of 3D printing with ease, without worrying about complex 3D model building. Nexprint is here to offer countless 3D designs and deliver seamless one-click workflow for everyone:

  • It is optimized for Elegoo printers by combining official model libraries with user-generated content for an enhanced printing experience.
  • It is integrated with Elegoo Slicer and OrcaSlicer to ensure a smooth workflow from model selection to printing with most 3D printers in the market.
  • It aggregates 3D models from platforms other than Nexprint, making it easy to browse and download high-quality models without switching between platforms.

The process will be made accessible for everyone, regardless of their skill levels or printer preference. This is possible because hundreds of thousands of creators contribute their designs. We greatly value each creator’s contribution to Nexprint community and encourage them to keep sharing their most creative and original designs. They will be rewarded with the following benefits:

  • A points-based rewarding system for creative designs.
  • Regular competitions with prizes for standout designs.
  • Priority exposure and platform-wide recommendations for top 3D models.
  • Dedicated support channels including support tickets and community engagement ensure rapid feedback for creators. 

“Nexprint is more than a platform—it’s a hub where creators can connect, innovate, and bring their ideas to life, while offering everyone seamless access to a world of inspiring models and immersive experiences,” said Ryan Siu, VP of Elegoo. “Our vision is to build an open, collaborative ecosystem driven by community feedback, empowering creators at every level to share, grow, and shape the future of digital creation. We’re really excited for what’s ahead.”

Currently in its early stages, Nexprint invites creators of all skill levels to join, contribute, and help shape its future as a global community. For more information please visit www.nexprint.com.

About Elegoo

Founded in 2015, Elegoo is a rapidly developing brand in the global smart manufacturing industry, specializing in R&D, manufacturing, and sales of consumer-grade 3D printers, laser engravers, STEM kits, and other smart technology products. Located in Shenzhen, the Silicon Valley of China, the company has sold millions of products across more than 100 countries and regions. In 2024, the company’s total sales revenue surpassed 220 million USD, with more than 1000 employees and nearly 30,000 square meters of office and manufacturing area. With a focus on programming and 3D printing technology, Elegoo provides unique and smart creation spaces for diverse consumers to enhance personalized experiences.

Alphamab Oncology Announces IND Application for Innovative PD-L1/αvβ6 Bispecific ADC JSKN022 was Officially Accepted by CDE

SUZHOU, China, Aug. 4, 2025 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN022, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and integrin αvβ6, has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The Company plans to initiate a first-in-human (FIH) clinical study of JSKN022 for the treatment of advanced malignant solid tumors.

JSKN022 is an innovative bispecific ADC developed in-house with Alphamab’s proprietary glycan-specific conjugation platform. The molecule simultaneously targets and binds to both PD-L1 and integrin αvβ6 on the surface of tumor cells. After binding to either target, JSKN022 enters the lysosome through target-mediated endocytosis. The cleavable linker is specifically hydrolyzed by proteolytic enzymes such as cathepsin B, releasing cytotoxic topoisomerase I inhibitor (T01), which then induces apoptosis of PD-L1 and/or integrin αvβ6 positive tumor cells. In addition, the inhibitor can penetrate the cell membrane and enter the antigen-negative tumor cells to exert bystander effects. These combined effects can effectively inhibit the growth of tumor cells.

At present, no ADC targeting integrin αvβ6 or PD-L1 has been approved for marketing worldwide, with all related investigational candidates remaining in clinical development stages. Preclinical data demonstrate that JSKN022 exhibits potent antitumor activity in both in vitro and in vivo models against tumor cells expressing integrin αvβ6 and/or PD-L1. JSKN022 will potentially bring in novelty in the therapeutic approach for cancers that are refractory or resistant to PD-1/PD-L1 inhibitors, including non-small cell lung cancer, head and neck squamous cell carcinoma, and colorectal cancer.

This Phase I clinical study will evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD), and antitumor activity of JSKN022 in patients with advanced malignant solid tumors who have failed standard therapies, and determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D).

About JSKN022
JSKN022 is a first-in-class ADC targeting both PD-L1 and integrin αvβ6. Based on independently developed Envafolimab, Alphamab integrates immuno-oncology (IO) mechanisms with ADC approaches. This novel drug molecule utilizes glycan-specific conjugation technology to enhance both stability and homogeneity. The topoisomerase I inhibitor T01 is site-specifically conjugated to antibodies via a cleavable linker, enhancing therapeutic efficacy. JSKN022 is expected to provide a novel therapeutic option for cancers that are refractory or resistant to PD-1/PD-L1 inhibitors. The IND application for the first-in-human clinical study of JSKN022 for the treatment of advanced malignant solid tumors has been accepted by CDE.

About Alphamab Oncology
Alphamab Oncology is an innovative biopharmaceutical company focusing on oncology therapeutics. On December 12, 2019, the Company was successfully listed on the Main Board of the Hong Kong Stock Exchange, trading under the stock code 9966.

By leveraging its proprietary core technology platforms including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payload, dual-payload antibody conjugation, and subcutaneous high concentration formulation for biologics, the Company has established a product portfolio with differentiated innovation and global competitiveness, covering cutting-edge areas such as antibody-drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies.

The Company has one product approved for marketing (Envafolimab, the world’s first subcutaneously injectable PD-(L)1 inhibitor), which has made a significant breakthrough in the convenience and accessibility of cancer treatment. Additionally, the Company has multiple bispecific antibodies and bispecific ADCs in clinical stage, while rapidly advancing the preclinical pipeline prioritizing bispecific ADCs and dual-payload ADCs. Multiple strategic collaborations based on innovative products or technology platforms have been established with partners such as CSPC, ArriVent, and Glenmark.

Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide.

 

Omni HR Acquires Singapore-Based MajuHR, Strengthening Its Position in Asia’s HR Tech Market

SINGAPORE, Aug. 4, 2025 /PRNewswire/ — People Intelligence Singapore Pte. Ltd. (“Omni HR”) today announced the acquisition of MajuHR, a Singapore-based HR software company, for an undisclosed amount. This marks Omni’s first acquisition and a strategic step toward consolidating Asia’s fragmented HR technology landscape.

Strong growth drives expansion

Singapore-based Omni HR provides cloud-based HR and payroll solutions across 15+ Asian markets, offering automated workflows alongside local compliance capabilities. The company’s $7.4 million funding round in 2024 and rapid customer growth set the stage for its first acquisition.

MajuHR is a pioneer in omnichannel-native HR software in Southeast Asia, letting employees request time off or check their payslips through a simple WhatsApp message—the way many Asian teams already communicate. By integrating MajuHR’s chat-native DNA with Omni HR’s multi-country capabilities, the combined platform will deliver more intuitive HR experiences tailored to how modern Asian teams operate.

Market demands modern solutions

The deal reflects growing demand in Asia’s $6.4 billion HR software market for platforms that actually understand how business gets done in the region, combining sophisticated automation with regional compliance expertise—capabilities that many local providers have been slow to develop.

“At Omni HR, our focus has always been on bringing automation and flexible workflows to modern teams operating across borders in Asia. The acquisition of MajuHR allows us to deepen our product capabilities and broaden our client portfolio,” said Brian Ip, Founder & CEO of Omni HR.

“Omni’s track record in multi-country employee management across Asia is second to none. We’re thrilled to bring our chat-native DNA under the Omni banner and collectively unlock a more seamless, data-rich experience for HR and Finance leaders across the region,” said Roshan Ravishankar, Co-founder of MajuHR.

MajuHR’s customer base will transition to Omni HR’s platform, adding to the company’s growing portfolio of modern, tech-forward businesses across the region.

The acquisition positions Omni HR as a key player among emerging Asian HR technology companies that are developing platforms competitive with global software providers while maintaining deep local market knowledge.

Looking ahead, Omni HR plans to continue investing in deeper localisation. The company is also exploring additional partnerships and product extensions to better serve growing mid-market and enterprise clients across Asia. With the acquisition of MajuHR, Omni lays the groundwork for future expansion via both product development and strategic M&A.

About Omni HR: Founded in 2021, Omni HR provides cloud-based HR and payroll software for companies scaling across Asia. The Singapore-based company offers automated workflows, multi-country payroll processing, performance management, and employee onboarding across all major Asian markets. Backed by leading investors including Picus Capital and Alpha JWC Ventures, Omni HR has raised $9.8 million in funding to-date. For more information, visit www.omnihr.co.

About MajuHR: MajuHR is a Singapore-based, omnichannel chat-native HR platform used by thousands across Southeast Asia to manage full-suite HR through consumer chat apps. Founded by Charlie Angriawan and Roshan Ravishankar, with founding team members Dipansh Bhatt and Madhusudan Murali.

Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics

Shilpa Medicare Serves as Lead Investor, Positioning Alveolus Bio for Phase 2 Clinical Trials and First-in-Human Studies

CAMBRIDGE, Mass. and BIRMINGHAM, Ala. and RAICHUR, India, Aug. 4, 2025 /PRNewswire/ — Alveolus Bio, a pioneering respiratory drug development biotech company founded by Dr. Vivek Lal from University of Alabama at Birmingham, AL, has announced a strategic financing round led by Shilpa Medicare Limited (BSE: 524742) (NSE: SHILPAMED), a prominent global pharmaceutical company with extensive expertise in respiratory therapeutics manufacturing and biotechnology innovation.

Through this collaboration, Shilpa Biologics, the biologics arm of Shilpa Medicare, will become Alveolus Bio’s exclusive global development and manufacturing partner. This partnership propels Alveolus Bio’s live biotherapeutics and small molecule platform towards Phase 2 and first-in-human clinical trials, with a lead asset for COPD progressing rapidly.

Shilpa Medicare brings deep experience in drug discovery, development, and manufacturing, along with strong regulatory capabilities. Their investment and strategic involvement will accelerate the clinical advancement of Alveolus Bio’s resMIT (respiratory microbiota-based inhaled therapeutics) platform. This novel platform enables targeted delivery of inhaled therapies to deep lung regions, addressing unmet needs in diseases such as COPD, Bronchopulmonary Dysplasia (BPD), and Pulmonary Fibrosis.

“Securing Shilpa as our lead investor is a transformative step,” said Gaurav Mehta, CEO of Alveolus Bio. “Their global pharmaceutical leadership aligns perfectly with our vision to redefine how lung diseases are treated.”

“Alveolus Bio’s breakthrough science is poised to transform respiratory care. Through this strategic partnership with Shilpa, we combine disruptive biotech innovation with world-class commercialization, bringing life-changing therapies faster to the market,” said Dr. C. Vivek Lal, Founder and CSO, Alveolus Bio.

“Shilpa has always focused on enabling breakthrough biologics,” said Vishnukant Bhutada, Managing Director, Shilpa Medicare. “This partnership strengthens our innovation pipeline and reinforces our role as a trusted global partner for biotech development.”

The financing round remains open to other strategic investors who share Alveolus Bio’s vision of transforming respiratory medicine.

About Shilpa Medicare
Shilpa Medicare is a global pharmaceutical company with capabilities across drug discovery to commercialization, specializing in respiratory therapeutics and biotech innovation. Visit www.vbshilpa.com.

About Alveolus Bio
A Biostack Ventures company, Alveolus Bio is developing first-in-class therapies for lung diseases using its proprietary resMIT platform. Its pipeline includes programs for COPD, BPD, Pulmonary Fibrosis, Cystic Fibrosis, and more.